Overview

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
To assess the safety and efficacy of intravenous (IV) PDA001 infused every two weeks for up to 5 total infusions in subjects with Crohn's disease who are refractory to one or more standard Crohn's disease therapies.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene Corporation
Celularity Incorporated